Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

• Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
  
• Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 6 [ Time Frame: Baseline, Month 6 ] [ Designated as safety issue: No ]
  
• Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 12 [ Time Frame: Baseline, Month 12 ] [ Designated as safety issue: No ]
  
• Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Counts at Month 3 [ Time Frame: Baseline, Month 3 ] [ Designated as safety issue: No ]
  
• Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Counts at Month 6 [ Time Frame: Baseline, Month 6 ] [ Designated as safety issue: No ]
  
• Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Counts at Month 12 [ Time Frame: Baseline, Month 12 ] [ Designated as safety issue: No ]
  
• Number of Participants With Centers for Disease Control and Prevention (CDC) Classification at Month 3 [ Time Frame: Month 3 ] [ Designated as safety issue: No ]
  Participants were classified based on the severity as mild (Category A), moderate (Category B), and severe (Category C).
  
  
• Number of Participants With Centers for Disease Control and Prevention (CDC) Classification at Month 6 [ Time Frame: Month 6 ] [ Designated as safety issue: No ]
  Participants were classified based on the severity as mild (Category A), moderate (Category B), and severe (Category C).
  
  
• Number of Participants With Centers for Disease Control and Prevention (CDC) Classification at Month 12 [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
  Participants were classified based on the severity as mild (Category A), moderate (Category B), and severe (Category C).
  
  

• Change From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Overall Score at Months 6 and 12 [ Time Frame: Baseline, Months 6, 12 ] [ Designated as safety issue: No ]
  SDM consists of the 20 items questionnaire, each item rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health). A positive change from baseline indicates a decline in a participant's quality of life over that period.
  
  
• Number of Participants With Human Immunodeficiency Virus (HIV) Response [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
  Response was defined as a HIV-1 RNA count of less than 50 copies/mL.
  
  
• Physician's Assessment of Efficacy [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
  Number of participants with each grade of efficacy as assessed by the physician was reported on the 5 point categorical scale: excellent, very good, good, fair, poor.
  
  
• Number of Participants Taking Concomitant Therapy [ Time Frame: Baseline, Month 12 ] [ Designated as safety issue: No ]
  Participants taking HIV/AIDS concomitant medication at Month 12, at Baseline and Month 12 were reported. It included Emtricitabine/tenofovir disoproxil fumarate(FTC/TDF),Raltegravir(RAL), Ritonavir (RTV), Darunavir(DRV), Kaletra, Atazanavir sulfate(ATV), Abacavir sulfate/lamivudine(ABC/LAM), Tenofovir disoproxil fumarate(TDF), Etravirine(ETR), Lamivudine (LAM), Zidovudine W/lamivudine(ZDV W/LAM), Nevirapine(NVP), Saquinavir mesilate(SQV), Trizivir(TZV), Zidovudine(ZDV), Abacavir sulfate(ABC), Emtricitabine(FTC),Entecavir(ETV).
  
  

Non interventional study, inclusion and exclusion criteria defined by the labelling of Celsentri (Maraviroc).